Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma

被引：0
|
作者：
Liu, Wei
Huang, Wenyang
Lv, Ryu
Deng, Shuhui
Yi, Shuhua
Liu, Huimin
Lv, Lulu
Qiu, Lugui
Zou, Dehui
Wang, Jianxiang
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139351
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist
    Jacobson, Caron A.
    Farooq, Umar
    Ghobadi, Armin
    ONCOLOGIST, 2020, 25 (01): : E138 - E146
  • [32] CNCT19 for Treatment of Patients with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-cell ALL) in Children and Adults
    Wang, Ying
    Chen, Xiaojuan
    Wei, Shuning
    Mi, Yingchang
    Shi, Lin
    Wang, Ying
    Wang, Yongzeng
    Haudenschild, Changting
    Lv, Lulu
    Zhu, Xiaofan
    Wang, Jianxiang
    BLOOD, 2021, 138
  • [33] A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off
    Leroy, Marie
    Deramoudt, Laure
    Pinturaud, Marine
    Demaret, Julie
    Alidjinou, Enagnon Kazali
    Nudel, Morgane
    Cavalieri, Doriane
    Chahla, Wadih Abou
    Odou, Pascal
    Morschhauser, Franck
    Yakoub-Agha, Ibrahim
    Simon, Nicolas
    Beauvais, David
    LEUKEMIA & LYMPHOMA, 2024, 65 (06) : 868 - 871
  • [34] Anti-CD19 chimeric antigenic receptor T cell as a second-line therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
    Naqvi, Syed Arsalan Ahmed
    Asghar, Noureen
    Sipra, Qurat Ul Ain Riaz
    Paludo, Jonas
    Bin Riaz, Irbaz
    Husnain, Muhammad
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
    Pier Luigi Zinzani
    Giorgio Minotti
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 177 - 190
  • [36] Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
    Zinzani, Pier Luigi
    Minotti, Giorgio
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 177 - 190
  • [37] Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
    Cao, Yaqing
    Lu, Wenyi
    Sun, Rui
    Jin, Xin
    Cheng, Lin
    He, Xiaoyuan
    Wang, Luqiao
    Yuan, Ting
    Lyu, Cuicui
    Zhao, Mingfeng
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [38] Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy
    Perez, Arianne
    Navale, Lynn
    Rossi, John M.
    Shen, Yueh-wei
    Jiang, Yizhou
    Sherman, Marika
    Mardiros, Armen
    Yoder, Sean C.
    Go, William Y.
    Rosenberg, Steven A.
    Wiezorek, Jeff
    Roberts, Margo R.
    Chang, David D.
    Kochenderfer, James N.
    Bot, Adrian
    BLOOD, 2015, 126 (23)
  • [39] Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis
    Di Blasi, Roberta
    Le Gouill, Steven
    Bachy, Emmanuel
    Cartron, Guillaume
    Beauvais, David
    Le Bras, Fabien
    Gros, Francois-Xavier
    Choquet, Sylvain
    Bories, Pierre
    Feugier, Pierre
    Casasnovas, Olivier
    Bay, Jacques Olivier
    Mohty, Mohamad
    Joris, Magalie
    Gastinne, Thomas
    Sesques, Pierre
    Tudesq, Jean-Jacques
    Vercellino, Laetitia
    Morschhauser, Franck
    Gat, Elodie
    Broussais, Florence
    Houot, Roch
    Thieblemont, Catherine
    BLOOD, 2022, 140 (24) : 2584 - 2593
  • [40] CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) - the Munich Real Life Experience
    Buecklein, V.
    Schmidt, C.
    Blumenberg, V.
    Reischer, A.
    von, Baumgarten L.
    Voelkl, A.
    Wagner, B.
    Humpe, A.
    Reilich, S.
    Bauer, M.
    Ostermann, H.
    Tischer, J.
    Stemmler, H-J.
    von Bergwelt, M.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 80 - 81
12345